Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on May 31, 2023 1:49pm
147 Views
Post# 35473034

RE:RE:RE:RE:Any value creation soon

RE:RE:RE:RE:Any value creation soon

There won't be a formal presentation to go with the poster, it not how it usually works, unless things have changed. Before Covid and online conferences you just stood by your poster and chatted with anybody who stopped. The poster really says it all.


Wino115 wrote: I believe it was Marsolais or someone recently that used the term "interim check" or something to that effect.  I suppose our first real read will be what the real expert says at the poster or paper presentation. She won't sugar coat it and has no reason to.  I would love a transcript of the presenation and if there's a Q&A, that would be revealing.  THTX should post a transcript of it or some kind of summary with actual quotes --the good, the bad and the ugly.  Just get the transparency around the past results out of the way and expectations realistic on what they need to do with any new protocols and why the tweaks "could" address some to get an SD to a CR. Next week will be the beginning of trying to see what it was about and where it is.

 

<< Previous
Bullboard Posts
Next >>